A phase II exploratory, multicentre, open-label, non-comparative study of ZD1839 (IressaTM) and radiotherapy in the treatment of patients with glioblastoma multiforme.

Trial Profile

A phase II exploratory, multicentre, open-label, non-comparative study of ZD1839 (IressaTM) and radiotherapy in the treatment of patients with glioblastoma multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 May 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 01 Sep 2006 Status change
    • 01 Sep 2006 The expected completion date for this trial is now 1 May 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top